Clinical Trial Update: Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating relugolix and enzalutamide with radiation therapy for very high risk prostate cancer (OPTIMAL trial) is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ORGOVYX (RELUGOLIX)
• Xtandi (enzalutamide)

Snippet

Sponsor: Northwestern University | Conditions: Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING